Comparable diagnostic accuracy seen for HPV testing for detection of CIN2+ and CIN3+<\/p>\n<\/h3>\n
By Elana Gotkine HealthDay Reporter<\/b>
\n<\/b><\/p>\n
MONDAY, Feb. 9, 2026 (HealthDay News) — For human papillomavirus (HPV) testing for detection of cervical intraepithelial neoplasia grade 2\/3 or worse (CIN2+\/CIN3+), minipad-collected menstrual blood shows comparable diagnostic accuracy to clinician-collected cervical samples, according to a study published online Feb. 4 in The BMJ<\/em>.<\/p>\n Xun Tian, from the Huazhong University of Science and Technology in Wuhan, China, and colleagues conducted a cross-sectional population-based study involving 3,068 women aged 20 to 54 years with regular menstrual cycles to compare the diagnostic accuracy of minipad-collected menstrual blood versus clinician-collected cervical samples to test for HPV in the detection of CIN2+\/CIN3+.<\/p>\n The researchers found that minipad-based HPV testing showed a sensitivity of 94.7 percent for CIN2+ detection, which was comparable to the 92.1 percent sensitivity of clinician-based HPV testing. Minipad HPV testing showed lower specificity than clinician-based testing (89.1 versus 90.0 percent), but the negative predictive value was the same (99.9 percent). A similar positive predictive value was seen for both collection methods (9.9 versus 10.4 percent), and screening efficiency was also similar (10.1 versus 9.6 referrals per CIN2+ detected).<\/p>\n “These findings support the integration of menstrual blood-based HPV testing into national cervical cancer screening guidelines,” the authors write.<\/p>\n One author disclosed ties to Organon, Celmatix, and Exeltis.<\/p>\n Abstract\/Full Text (subscription or payment may be required)<\/a><\/p>\n